Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Two distinct effectors of the small GTPase Rab5 cooperate in endocytic membrane fusion.

The EMBO journal | 1998

Using the yeast two-hybrid system, we have identified a novel 62 kDa coiled-coil protein that specifically interacts with the GTP-bound form of Rab5, a small GTPase that regulates membrane traffic in the early endocytic pathway. This protein shares 42% sequence identity with Rabaptin-5, a previously identified effector of Rab5, and we therefore named it Rabaptin-5beta. Like Rabaptin-5, Rabaptin-5beta displays heptad repeats characteristic of coiled-coil proteins and is recruited on the endosomal membrane by Rab5 in a GTP-dependent manner. However, Rabaptin-5beta has features that distinguish it from Rabaptin-5. The relative expression levels of the two proteins varies in different cell types. Rabaptin-5beta does not heterodimerize with Rabaptin-5, and forms a distinct complex with Rabex-5, the GDP/GTP exchange factor for Rab5. Immunodepletion of the Rabaptin-5beta complex from cytosol only partially inhibits early endosome fusion in vitro, whereas the additional depletion of the Rabaptin-5 complex has a stronger inhibitory effect. Fusion activity can mostly be recovered by addition of the Rabaptin-5 complex alone, but maximal fusion efficiency requires the presence of both Rabaptin-5 and Rabaptin-5beta complexes. Our results suggest that Rab5 binds to at least two distinct effectors which cooperate for optimal endocytic membrane docking and fusion.

Pubmed ID: 9524116 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


iGen (tool)

RRID:SCR_009433

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Certified clinical laboratory (ISO15189). To clinicians in oncology we offer genetic and epigenetic analyses together with interpretation. iGen also provides professional genetic counseling ?????????????????? a healthcare service, which advises people who are at the risk of hereditary cancer. In the research field iGen performs assay development and genotyping services. Our customers are clinical laboratories, research groups and genetic tests distributors. To improve molecular diagnostics in cancer treatment iGen is continuously carrying out research and applied science projects. Currently, our main cooperation partners are the Competence Centre of Cancer Research and North Estonian Medical Centre. We are looking for other cooperation opportunities, and are interested in participating in national and international cooperative research projects, to which we can contribute with our expertise in molecular diagnostics. Our laboratory and office are situated in Tehnopol Tallinn Science Park territory, next to the campus of Tallinn University of Technology. Prices quoted are highly dependable on the number of samples and are given based on full plate/machine, please contact us for pricing for smaller projects.

View all literature mentions

New England Biolabs (tool)

RRID:SCR_013517

An Antibody supplier

View all literature mentions